cfr_sections
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
24 rows where part_number = 510 and title_number = 21 sorted by section_id
This data as json, CSV (advanced)
Suggested facets: subpart, subpart_name, amendment_citations
| section_id ▼ | title_number | title_name | chapter | subchapter | part_number | part_name | subpart | subpart_name | section_number | section_heading | agency | authority | source_citation | amendment_citations | full_text |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21:21:6.0.1.1.6.1.1.1 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | A | Subpart A—General Provisions | § 510.3 Definitions and interpretations. | FDA | [40 FR 13807, Mar. 27, 1975, as amended at 50 FR 7517, Feb. 22, 1985; 54 FR 22741, May 26, 1989; 64 FR 69190, Dec. 10, 1999; 72 FR 41017, July 26, 2007] | As used in this part: (a) The term act means the Federal Food, Drug, and Cosmetic Act, as amended (secs. 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392). (b) Department means the Department of Health and Human Services. (c) Secretary means the Secretary of Health and Human Services. (d) Commissioner means the Commissioner of Food and Drugs. (e) Person means individuals, partnerships, corporations, and associations. (f) The definitions and interpretations of terms contained in section 201 of the act shall be applicable to such terms when used in the regulations in this part. (g) The term new animal drug means any drug intended for use for animals other than man, including any drug intended for use in animal feed but not including such animal feed: (1) The composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling thereof; except that such a drug not so recognized shall not be deemed to be a new animal drug if at any time prior to June 25, 1938, it was subject to the Food and Drug Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use; or (2) The composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions. (h) The term animal feed means an article which is intended for use for food for animals other than man and which is intended for use as a substantial source of nutrients in the diet of the animal, and is not limited to a mixture intended to be the sole ration of the animal. (i) The newness of an animal drug, i… | |||
| 21:21:6.0.1.1.6.1.1.2 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | A | Subpart A—General Provisions | § 510.4 Biologics; products subject to license control. | FDA | An animal drug produced and distributed in full conformance with the animal virus, serum, and toxin law of March 4, 1913 (37 Stat. 832; 21 U.S.C. 151 et seq. ) and any regulations issued thereunder shall not be deemed to be subject to section 512 of the Federal Food, Drug, and Cosmetic Act. | ||||
| 21:21:6.0.1.1.6.1.1.3 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | A | Subpart A—General Provisions | § 510.7 Consignees of new animal drugs for use in the manufacture of animal feed. | FDA | [40 FR 13807, Mar. 27, 1975, as amended at 64 FR 63203, Nov. 19, 1999] | (a) A new animal drug intended for use in the manufacture of animal feed shall be deemed to be unsafe unless at the time of its removal from the establishment of a manufacturer, packer, or distributor of such drug, such manufacturer, packer, or distributor has an unrevoked written statement from the consignee of such drug, or a notice from the Secretary, to the effect that with respect to the use of such drug in animal feed the consignee: (1) Holds a license issued under § 515.20 of this chapter; or (2) Will, if the consignee is not the user of the drug, ship such drug only to a holder of an approved application under § 515.10 of this chapter. (b) The requirements of paragraph (a) of this section do not apply: (1) Where such drugs are intended for export and/or (2) When the use of such drug in the manufacture of a finished feed has been exempted from the requirements of section 512(m) of the act under the conditions specified by regulations published in part 558 of this chapter. | |||
| 21:21:6.0.1.1.6.1.1.4 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | A | Subpart A—General Provisions | § 510.95 [Reserved] | FDA | |||||
| 21:21:6.0.1.1.6.2.1.1 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | B | Subpart B—Specific Administrative Rulings and Decisions | § 510.105 Labeling of drugs for use in milk-producing animals. | FDA | [40 FR 13807, Mar. 27, 1975, as amended at 63 FR 32980, June 17, 1998; 64 FR 51241, Sept. 22, 1999] | (a) Part 526 of this chapter provides for new animal drugs intended for intramammary use in animals and includes conditions of use intended to prevent the contamination of milk from the use of such drugs. (b) Preparations containing antibiotics and other potent drugs labeled with directions for use in milk-producing animals will be misbranded under section 502(f)(2) of the act unless their labeling bears appropriate warnings and directions for use to avoid adulteration of milk under section 402(a)(2)(c)(ii) of the act. (c) It is the position of the Food and Drug Administration that the labeling for such preparations should bear a clear warning that either: (1) The article should not be administered to animals producing milk, since to do so would result in contamination of the milk; or (2) The label should bear the following statement: “Warning: Milk that has been taken from animals during treatment and for __ hours after the latest treatment must not be used for food”, the blank being filled in with the figure that the manufacturer has determined by appropriate investigation is needed to insure that the milk will not carry violative residues resulting from use of the preparation. If the use of the preparation as recommended does not result in contamination of the milk, neither of the above warning statements is required. | |||
| 21:21:6.0.1.1.6.2.1.2 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | B | Subpart B—Specific Administrative Rulings and Decisions | § 510.106 Labeling of antibiotic and antibiotic-containing drugs intended for use in milk-producing animals. | FDA | [63 FR 32980, June 17, 1998] | Whenever the labeling of an antibiotic drug included in the regulations in this chapter suggests or recommends its use in milk-producing animals, the label of such drugs shall bear either the statement “Warning: Not for use in animals producing milk, since this use will result in contamination of the milk” or the statement “Warning: Milk that has been taken from animals during treatment and for __hours after the latest treatment must not be used for food”, the blank being filled in with the figure that the Commissioner has authorized the manufacturer of the drug to use. The Commissioner shall determine what such figures shall be from information submitted by the manufacturer and which the Commissioner considers is adequate to prove that period of time after the latest treatment that the milk from treated animals will contain no violative residues from use of the preparation. If the Commissioner determines from the information submitted that the use of the antibiotic drug as recommended does not result in its appearance in the milk, the Commissioner may exempt the drug from bearing either of the above warning statements. | |||
| 21:21:6.0.1.1.6.2.1.3 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | B | Subpart B—Specific Administrative Rulings and Decisions | § 510.110 Antibiotics used in food-producing animals. | FDA | [40 FR 13807, Mar. 27, 1975, as amended at 54 FR 18280, Apr. 28, 1989; 64 FR 403, Jan. 5, 1999] | (a) The Food and Drug Administration in the interest of fulfilling its responsibilities with regard to protection of the public health has requested an evaluation of the public health aspects of the use of antibiotics in veterinary medical and nonmedical uses. There is particular concern with regard to the potential hazards associated with the extensive use of antibiotics administered to food-producing animals. Accordingly, an ad hoc committee on the Veterinary Medical and Nonmedical Uses of Antibiotics was established by the Food and Drug Administration to study and advise the Commissioner of Food and Drugs on the uses of antibiotics in veterinary medicine and for various nonmedical purposes as such uses may affect the enforcement of the Federal Food, Drug, and Cosmetic Act with respect to their safety and effectiveness. (b) Based upon an evaluation of the conclusions of said Committee and other relevant material, § 510.112 was published in the Federal Register of August 23, 1966 (31 FR 11141), asking sponsors of drugs containing any antibiotic intended for use in food-producing animals to submit data to establish whether such antibiotic and its metabolites are present as residues in edible tissues, milk, and eggs from treated animals. The data on the residues of antibiotics in milk from intramammary infusion preparations were requested within 60 days and the data on all other products were requested within 180 days following the date of publication of § 510.112 in the Federal Register. (c) An evaluation of the data now available shows that use of many antibiotic preparations cause residues in edible products of treated animals for varying and, in some cases, for long periods of time following the last administration. Because of the accumulation of new information with regard to the development of resistance of bacteria to antibiotics, the ability of bacteria to transfer this resistance, and the development of sensitivity to antibiotics in humans, unauthorized and unsafe residues of antibiotics cannot be pe… | |||
| 21:21:6.0.1.1.6.2.1.4 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | B | Subpart B—Specific Administrative Rulings and Decisions | § 510.112 Antibiotics used in veterinary medicine and for nonmedical purposes; required data. | FDA | [40 FR 13807, Mar. 27, 1975, as amended at 46 FR 8460, Jan. 27, 1981; 54 FR 18280, Apr. 28, 1989; 57 FR 6475, Feb. 25, 1992] | (a) An ad hoc committee, Committee on the Veterinary Medical and Nonmedical Uses of Antibiotics, was formed by the Food and Drug Administration to study, and advise the Commissioner on, the use of antibiotics in veterinary medicine and for various nonmedical purposes as such uses may affect the enforcement of the Federal Food, Drug, and Cosmetic Act with respect to the safety and effectiveness of such substances. A copy of the report may be obtained from the Food and Drug Administration, Office of Public Affairs, Room 15-05, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. (b) On the basis of the report of the Committee and other information, sponsors of drugs containing any antibiotic intended for use in food-producing animals shall submit data for determining whether or not such antibiotics and their metabolites are present as residues in edible tissues, milk, and eggs from treated animals; however, in the case of a drug for which such data have already been submitted and for which a regulation has been promulgated under section 409 of the act, only such data as has been accumulated since the issuance of the regulation need be submitted. (c) The required data shall be submitted within 180 days of the date of publication of this section in the Federal Register ; except that in the case of data on intramammary infusion preparations the data shall be submitted within 60 days of such publication. Data demonstrating the absence in milk of residues of intramammary infusion preparations when used as directed in their labeling are needed within the 60-day period because of the importance of milk in the human diet. (d) Regulatory proceedings including revocation of prior sanctions, or actions to suspend or amend new drug or antibiotic approvals granted prior to passage of the Food Additives Amendment of 1958 (72 Stat. 1784), may be initiated with regard to the continued marketing of any antibiotic preparation on which the required information is not submitted within the period of time prescribed by paragra… | |||
| 21:21:6.0.1.1.6.3.1.1 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.201 Scope. | FDA | This subpart applies to tolerances for residues of new animal drugs not approved or conditionally approved for use in the United States, but lawfully used in another country and present in imported, animal-derived food and food products. | ||||
| 21:21:6.0.1.1.6.3.1.10 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.213 Administrative stay of action. | FDA | (a) The Commissioner may at any time, on his or her own initiative or on the request of an interested person under part 10 of this chapter, stay or extend the effective date of a decision to establish, not establish, amend, or revoke an import tolerance. (b) A request for stay must be submitted in accordance with § 10.20 of this chapter and in the form specified in § 10.35 of this chapter no later than 30 days after public notification of the decision involved. The Commissioner may, for good cause, permit a petition to be filed more than 30 days after public notification of the decision. | ||||
| 21:21:6.0.1.1.6.3.1.2 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.202 Definitions. | FDA | The following definitions of terms apply when used in this subpart: CNADA means an application for conditional approval of a new animal drug submitted under section 571 of the Federal Food, Drug, and Cosmetic Act, and includes all amendments and permissible supplements. Import tolerance means a tolerance for a residue of a new animal drug not approved or conditionally approved for use in the United States, but present in any imported edible portion of any animal. NADA means a new animal drug application submitted under section 512 of the Federal Food, Drug, and Cosmetic Act, including all amendments and permissible supplements, for approval of a new animal drug. Request means a request to establish or amend an import tolerance. | ||||
| 21:21:6.0.1.1.6.3.1.3 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.203 Initiation of a proceeding to establish or amend an import tolerance. | FDA | (a) Any interested person may request that the Commissioner establish or amend an import tolerance. Such a request must be in the form specified in § 510.205 of this chapter. (b) The Commissioner may initiate a proceeding to establish or amend an import tolerance on his or her own initiative pursuant to § 10.25(b) of this chapter. | ||||
| 21:21:6.0.1.1.6.3.1.4 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.205 Content and administration of a request. | FDA | (a) Pertinent information previously submitted to and currently retained in the files of the Food and Drug Administration (FDA) may be incorporated in, and will be considered as part of, a request on the basis of specific reference to such information. If the requester refers to any nonpublic information other than its own, the requester shall obtain a written right of reference to that nonpublic information and submit the right of reference with the request. Any reference to published information offered in support of a request should be accompanied by reprints or copies of such references. (b) Requests shall be submitted and addressed to the Document Control Unit (HFV-199), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Requests may be submitted in an electronic format as authorized by FDA. See FDA′s Electronic Submissions Gateway website: https://www.fda.gov/industry/electronic-submissions-gateway. (c) Any material submitted in a foreign language shall be accompanied by a complete and accurate English translation. Translations of literature printed in a language other than English shall be accompanied by copies of the original publication. (d) The request must be dated and must be signed by the requester or by his or her authorized attorney, agent, or official and shall state the requester's correspondence address. If the requester or such authorized representative does not reside or have a place of business within the United States, the requester must also furnish the name and post office address of, and the request must be countersigned by, an authorized attorney, agent, or official residing or maintaining a place of business within the United States. (e) The request must include the following information: (1) The established name and all pertinent information concerning the new animal drug, including chemical identity and composition of the new animal drug, and its physical, chemical, and biological properties; (2) The conditions of use for the n… | ||||
| 21:21:6.0.1.1.6.3.1.5 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.206 Review of information supporting actions to establish or amend an import tolerance. | FDA | In establishing or amending an import tolerance, the Commissioner shall rely on data sufficient to demonstrate that a proposed tolerance is safe based on similar food safety criteria used by the Commissioner to establish tolerances for applications for new animal drugs filed under section 512(b)(1) of the Federal Food, Drug, and Cosmetic Act. In establishing or amending an import tolerance, the Commissioner will give appropriate consideration to the anticipated residue concentrations and conditions of use of the new animal drug specified. | ||||
| 21:21:6.0.1.1.6.3.1.6 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.207 Disclosure of information submitted in a request. | FDA | (a) When a request is determined to be complete for FDA's consideration, the Commissioner will provide public notification of the request containing the name of the requester and a brief description of the request in general terms. A copy of the notification will be sent to the requester at the time the information is made available to the public. (b) Any notification establishing, amending, or revoking an import tolerance will be made publicly available. A summary of the basis for the decision will be publicly released in accordance with the provisions of part 20 of this chapter. If FDA determines that the new animal drug referred to in the request is a new animal drug that induces cancer when ingested by people or animals, and the requester complies with the requirements of §§ 500.80 through 500.92 of this chapter (Subpart E, Regulation of Carcinogenic Compounds Used in Food-Producing Animals), the regulatory method for ascertaining the marker residue in the target tissue will be made publicly available. All information and safety data submitted with the request, or previously submitted information incorporated in, and considered as part of, a request on the basis of specific reference to such information, shall be available for public disclosure, also in accordance with the provisions of part 20 of this chapter. Trade secrets and confidential commercial or financial information are exempted from release under § 20.61 of this chapter. | ||||
| 21:21:6.0.1.1.6.3.1.7 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.209 Establishment, denial, or amendment of an import tolerance. | FDA | (a) If an import tolerance is established or amended, the Commissioner will provide public notification of the action, which will be effective from the date of public notification. A copy of the notification will be sent to any requestor at the time the information is made available to the public. (b) If a request to establish or amend an import tolerance is denied, a notification of the denial will be made publicly available, and a copy of the denial letter, including the reasons for such action, will be sent to the requester. (c) A tolerance established in an approved NADA or conditionally approved CNADA will supersede an existing import tolerance. In the event the conditionally approved CNADA is not renewed or is withdrawn, or such drug does not achieve approval under section 512 of the Federal Food, Drug, and Cosmetic Act within 5 years following the date of the conditional approval, the Agency will reinstate the import tolerance unless § 510.210(a)(1) or (a)(2) is applicable at that time. | ||||
| 21:21:6.0.1.1.6.3.1.8 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.210 Revocation of an import tolerance. | FDA | (a) The Commissioner, on his or her own initiative or on the petition of an interested person, under § 10.25 of this chapter, may revoke an import tolerance if: (1) Scientific evidence shows an import tolerance to be unsafe; or (2) Information demonstrates that the use of a new animal drug under actual use conditions results in food being imported into the United States with residues exceeding the import tolerance. (b) The Commissioner will provide public notification under § 510.207(b) that will specify the basis for the decision and will be effective at the time the information is made available to the public. (c) A petition for revocation must be submitted in the form specified in § 10.30 of this chapter. | ||||
| 21:21:6.0.1.1.6.3.1.9 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | C | Subpart C—Import Tolerances for Residues of Unapproved New Animal Drugs in Food | § 510.212 Administrative reconsideration of action. | FDA | (a) The Commissioner may at any time, on his or her own initiative or on the petition of an interested person under part 10 of this chapter, reconsider part or all of a decision to establish, not establish, amend, or revoke an import tolerance. (b) A petition for reconsideration must be submitted in accordance with § 10.20 of this chapter and in the form specified in § 10.33 of this chapter no later than 30 days after the date of public notification of the decision involved. The Commissioner may, for good cause, permit a petition to be filed more than 30 days after public notification of the decision. The petition for reconsideration must demonstrate that relevant information contained in the administrative record was not previously or not adequately considered by the Commissioner. No new information may be included in a petition for reconsideration. (c) An interested person who wishes to rely on information not included in the administrative record shall submit either a petition to amend an import tolerance under § 510.205 or to revoke an import tolerance under § 510.210 and § 10.25 of this chapter. | ||||
| 21:21:6.0.1.1.6.4.1.1 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | D | Subpart D—Records and Reports | § 510.301 Records and reports concerning experience with animal feeds bearing or containing new animal drugs for which an approved medicated feed mill license application is in effect. | FDA | [40 FR 13807, Mar. 27, 1975, as amended at 54 FR 18280, Apr. 28, 1989; 72 FR 69121, Dec. 6, 2007] | Records and reports of clinical and other experience with the new animal drug will be maintained and reported, appropriately identified with the new animal drug application(s) or index listing(s) to which they relate, to the Center for Veterinary Medicine in duplicate in accordance with the following: (a) Immediately upon receipt by the applicant, complete records or reports covering information of the following kinds: (1) Information concerning any mixup in the new animal drug or its labeling with another article. (2) Information concerning any bacteriological or any significant chemical, physical, or other change or deterioration in the drug, or any failure of one or more distributed batches of the drug to meet the specifications established for it in the new animal drug application or request for determination of eligibility for indexing. (b) As soon as possible, and in any event within 15 working days of its receipt by the applicant, complete records or reports concerning any information of the following kinds: (1) Information concerning any unexpected side effect, injury, toxicity, or sensitivity reaction or any unexpected incidence or severity thereof associated with clinical uses, studies, investigations, or tests, whether or not determined to be attributable to the new animal drug, except that this requirement shall not apply to the submission of information described in a written communication to the applicant from the Food and Drug Administration as types of information that may be submitted at other designated intervals. Unexpected as used in this paragraph refers to conditions or developments not previously submitted as part of the new animal drug application or in support of the index listing or not encountered during clinical trials of the drug, or conditions or developments occurring at a rate higher than shown by information previously submitted as part of the new animal drug application or in support of the index listing or at a rate higher than encountered during such clinical trials. (2… | |||
| 21:21:6.0.1.1.6.4.1.2 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | D | Subpart D—Records and Reports | § 510.305 Maintenance of copies of approved medicated feed mill licenses to manufacture animal feed bearing or containing new animal drugs. | FDA | [64 FR 63203, Nov. 19, 1999, as amended at 72 FR 69121, Dec. 6, 2007] | Each applicant shall maintain in a single accessible location: (a) A copy of the approved medicated feed mill license (Form FDA 3448) on the premises of the manufacturing establishment; and (b) Approved or index listed labeling for each Type B and/or Type C feed being manufactured on the premises of the manufacturing establishment or the facility where the feed labels are generated. | |||
| 21:21:6.0.1.1.6.5.1.1 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | E | Subpart E—Requirements for Specific New Animal Drugs | § 510.410 Corticosteroids for oral, injectable, and ophthalmic use in animals; warnings and labeling requirements. | FDA | [49 FR 48535, Dec. 13, 1984] | (a) The Food and Drug Administration has received reports of side effects associated with the oral, injectable, and ophthalmic use of corticosteroid animal drugs. The use of these drugs administered orally or by injection has resulted in premature parturition when administered during the last trimester of pregnancy. Premature parturition may be followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids used in dogs, rabbits, and rodents during pregnancy have produced cleft palate in offspring. Use in dogs has resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca. Drugs subject to this section are required to carry the veterinary prescription legend and are subject to the labeling requirements of § 201.105 of this chapter. (b) In view of these potentially serious side effects, the Food and Drug Administration has concluded that the labeling on or within packaged corticosteroid-containing preparations intended for animal use shall bear conspicuously the following warning statement: Warning: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca. Warning: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticos… | |||
| 21:21:6.0.1.1.6.5.1.2 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | E | Subpart E—Requirements for Specific New Animal Drugs | § 510.440 Injectable iron preparations. | FDA | There has been an increasing interest in the use of injectable iron compounds for the prevention or treatment of iron-deficiency anemia in animals. Although some such preparations have been shown to be safe, such articles are regarded as new animal drugs within the meaning of the Federal Food, Drug, and Cosmetic Act. Accordingly, an approved new animal drug application is required prior to the marketing of such preparations within the jurisdiction of the act. In addition to the need for demonstrating the safety of such articles, the labeling of such preparations should not only recommend appropriate dosages of iron but also declare the amount (in milligrams) of available iron (Fe) per milliliter of the subject product. | ||||
| 21:21:6.0.1.1.6.5.1.3 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | E | Subpart E—Requirements for Specific New Animal Drugs | § 510.455 Requirements for free-choice medicated feeds. | FDA | [69 FR 30197, May 27, 2004, as amended at 72 FR 69121, Dec. 6, 2007] | (a) What is free-choice medicated feed? For the purpose of this part, free-choice medicated feed is medicated feed that is placed in feeding or grazing areas and is not intended to be consumed fully at a single feeding or to constitute the entire diet of the animal. Free-choice feeds include, but are not limited to, medicated blocks (agglomerated feed compressed or rendered into a solid mass and cohesive enough to hold its form), mineral mixes, and liquid feed tank supplements (“lick tank” supplements) containing one or more new animal drugs. The manufacture of medicated free-choice feeds is subject to the current good manufacturing practice regulations in part 225 of this chapter for medicated feeds. (b) What is required for new animal drugs intended for use in free-choice feed? Any new animal drug intended for use in free-choice feed must be approved for such use under section 512 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360(b)) or listed in the index under section 572 of the act (21 U.S.C. 360ccc-1). Such approvals under section 512 of the act must be: (1) An original new animal drug application (NADA), (2) A supplemental NADA, or (3) An abbreviated NADA. (c) What are the approval requirements under section 512 of the act for new animal drugs intended for use in free-choice feed? An approval under section 512 of the act for a Type A medicated article intended for use in free-choice feed must contain the following information: (1) Data, or reference to data in a master file (MF), showing that the target animal consumes the new animal drug in the Type C free-choice feed in an amount that is safe and effective (consumption/effectiveness data); and (2) Data, or reference to data in an MF, showing the relevant ranges of conditions under which the drug will be chemically and physically stable in the Type C free-choice feed under field conditions. (d) How are consumption/effectiveness and/or stability data to be submitted? The data must be submitted as follows: (1) Directly in… | |||
| 21:21:6.0.1.1.6.7.1.1 | 21 | Food and Drugs | I | E | 510 | PART 510—NEW ANIMAL DRUGS | G | Subpart G—Sponsors of Approved Applications | § 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications. | FDA | [40 FR 13807, Mar. 27, 1975] | (a) Section 512(i) of the act requires publication of names and addresses of sponsors of approved applications for new animal drugs. (b) In this section each name and address is identified by a numerical drug labeler code. The labeler codes identify the sponsors of the new animal drug applications associated with the regulations published pursuant to section 512(i) of the act. The codes appear in the appropriate regulations and serve as a reference to the names and addresses listed in this section. The drug labeler code is established pursuant to section 510 of the act. (c) The names, addresses, and drug labeler codes of sponsors of approved new animal drug applications are as follows: (1) Alphabetical Listing of Sponsors (2) Numerical Listing of Sponsors |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE cfr_sections (
section_id TEXT PRIMARY KEY,
title_number INTEGER,
title_name TEXT,
chapter TEXT,
subchapter TEXT,
part_number TEXT,
part_name TEXT,
subpart TEXT,
subpart_name TEXT,
section_number TEXT,
section_heading TEXT,
agency TEXT,
authority TEXT,
source_citation TEXT,
amendment_citations TEXT,
full_text TEXT
);
CREATE INDEX idx_cfr_title ON cfr_sections(title_number);
CREATE INDEX idx_cfr_part ON cfr_sections(part_number);
CREATE INDEX idx_cfr_agency ON cfr_sections(agency);